Source: Eur Respir J 2014; 43: 1516-1519
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Shirai Yuichiro, Tamura Yuichi, Yasuoka Hidekata, Satoh Toru, Kuwana Masataka. IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. Eur Respir J 2014; 43: 1516-1519

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease Source: Eur Respir J 2009; 34: 1348-1356 Year: 2009 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Pulmonary arterial hypertension in the patients with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 512s Year: 2005 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Challenging cases in PH Source: Eur Respir Rev 2008; 17: 19-23 Year: 2007 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Pulmonary veno-occlusive disease misdiagnosed as idiopathic pulmonary arterial hypertension Source: Eur Respir Rev 2009; 18: 177-180 Year: 2009 Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Secondary pulmonary hypertension in chronic obstructive pulmonary disease and systemic lupus erythematosus- pathophysiology and treatment Source: Eur Respir J 2004; 24: Suppl. 48, 59s Year: 2004 Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015